TSX · BLCO.TO
Bausch + Lomb Corporation
CA$28.10-CA$0.65 (-2.26%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 5.48% below the high.
Loading market information…
TSX · IPCI.TO · CAD
Stock price, earnings
Quote as of Mar 5, 2024, 03:01 PM UTC. Cached market data; not a live quote.
One-year closing-price history · CAD. Historical prices are not a forecast.
Intellipharmaceutics International Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.94% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Intellipharmaceutics International Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Intellipharmaceutics International Inc., founded in Toronto, Canada, in 1998, is a pharmaceutical company that focuses on the research, development, and manufacturing of innovative and generic controlled-release and targeted-release oral solid dosage medications, primarily for the United States market. The company leverages its patented Hypermatrix technology to create advanced drug delivery systems, an array of product candidates, and a robust pipeline across diverse therapeutic areas, including neurological, cardiovascular, gastrointestinal, diabetes, and pain management conditions. Its current product portfolio includes extended-release formulations like Focalin XR for hyperactivity disorder, Keppra XR for partial onset seizures, Effexor XR to treat depression, and Protonix for gastroesophageal reflux disease. Other offerings feature Glucophage XR for type 2 diabetes, Seroquel XR for schizophrenia and mood disorders, Lamictal XR for epilepsy, Pristiq for depression, Coreg CR for heart failure and hypertension, and Ranexa for chronic angina. Furthermore, Intellipharmaceutics is actively developing additional controlled-release drugs such as OxyContin for pain relief and Regabatin XR for neuropathic pain management. The company operates under a license and commercialization agreement with Par Pharmaceutical Inc.
Latest available per-share figures in CAD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:19 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CA$28.10-CA$0.65 (-2.26%)
Bausch + Lomb Corporation’s quoted price sits in the upper half of its reported 52-week range, 5.48% below the high.
CA$33.48-CA$0.19 (-0.56%)
Apotex Health Corp.’s quoted price sits in the upper half of its reported 52-week range, 16.79% below the high.
CA$0.02CA$0.00 (0.0%)
ManifestSeven Holdings Corporation: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.00$0.00 (0.0%)
Aion Therapeutic Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.89% below the high.
CA$0.36CA$0.00 (0.0%)
Acerus Pharmaceuticals Corporation’s quoted price sits in the lower half of its reported 52-week range, 96.4% below the high.
CA$0.02CA$0.00 (0.0%)
Revitalist Lifestyle and Wellness Ltd.: Healthcare · Medical - Care Facilities.
CA$0.05CA$0.00 (0.0%)
Craftport Cannabis Corp.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.01$0.00 (0.0%)
MYND Life Sciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.0% below the high.
